CytoSorbents Corporation CTSO 深 沪
等待开盘 04-02 09:30:00 美东时间
0.5473
-0.019
-3.36%
华盛通- 最 高0.60
- 今 开0.60
- 成交量 7.63万股
- 最 低 0.54
- 昨 收 0.5663
- 总市值 3431.57万
- 52周最高 1.39
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.4992
- 委 比 33.79%
- 总股本 6270.00万
- 历史最高 15.24
- 量 比 0.50
- 振 幅 10.60%
- 历史最低 0.09
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ Cytosorbents(CTSO)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Cytosorbents业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年全年总收入3,710万美元，同比增长4%，创下核心产品销售记录 - Q4收入920万美元，同比增长1%，但按固定汇率计算下降8% - 德国以外直接国际销售860万美元，同比增长13% - 经销商销售1,650万美元，同比增长11.4% - 德国销售1,180万美元，同比下降10% **盈利能力：** - 全年毛利率71%，Q4毛利率74%，显示制造效率提升 - 全年运营亏损1,470万美元，同比改善10%（2024年为1,650万
03-27 12:16
CytoSorbents Q4 Adj. EPS $(0.07) Misses $(0.05) Estimate, Sales $9.234M Miss $9.587M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 50 percent increase over losses of $(0.14) per share from the same
03-26 04:11
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
CytoSorbents Hosts ISICEM 2026 Symposium in Brussels
CytoSorbents Hosts ISICEM 2026 Symposium in Brussels CytoSorbents attended the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels. The company hosted a featured symposium titled “Hemoadsorption as part of an individualized patient concept in Intensive Care - Key Le
03-19 21:45
CytoSorbents Corporation updates financial calendar with upcoming earnings report and webcast
CytoSorbents Corporation updates financial calendar with upcoming earnings report and webcast CytoSorbents Corporation (NASDAQ: CTSO) will report fourth quarter and full year 2025 financial results on Wednesday, March 25, 2026, with results released by the Company. Management will host a live presen
03-05 20:02
Watching Cytosorbents; Zacks Small-Cap Research Gives Stock $5 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01132026_CTSO_Kerr.pdf
01-14 02:12
CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75%
Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75%DrugSorb®-ATR De Novo
01-12 20:25
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.
2025-12-17 02:03
CytoSorbents Corporation Leadership Joins D. Boral Capital for Virtual Fireside Chat
CytoSorbents Corporation will participate in a virtual fireside chat with D. Boral Capital on Monday, December 15, 2025. CEO Dr. Phillip Chan and CFO Peter J. Mariani will join Jason Kolbert, Head of ...
2025-12-10 20:00
